FDA Grants Accelerated Approval to Neladalkib for ALK-Positive Lung Cancer

In this article
A New Targeted Drug for ALK-Positive Lung Cancer After Resistance: Neladalkib
The US Food and Drug Administration (FDA) granted accelerated approval to neladalkib (Nelkarmi, GSK) on 17 November 2026. The approval covers adults with unresectable locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who, in the advanced setting, have previously received either alectinib or at least two ALK inhibitors plus platinum-based chemotherapy. In the single-arm ALKOVE-1 trial on which the approval is based, the response rate in these two groups was 49% and 32%, respectively. This is a meaningful new option for patients whose disease has become resistant; however, the trial is not randomised, there is no control group and an effect on survival has not yet been shown. In this article I explain how neladalkib works, how the results should be read, its liver side effects, the indirect comparison with lorlatinib and the situation in Türkiye. I discussed first-line treatments for ALK-positive lung cancer in detail in my articles on alectinib and lorlatinib.
- What was approved? Neladalkib 150 mg by mouth once daily, in adults with advanced ALK-positive NSCLC who, in the advanced setting, have received only alectinib or at least two ALK inhibitors and platinum-based chemotherapy. This is an accelerated approval; clinical benefit must be confirmed for it to become permanent.
- How effective is it? The response rate was 49% after alectinib and 32% after more than one ALK inhibitor and chemotherapy. In about half of responders the response lasted longer than 12 months. Responses were also seen in brain metastases. Results are clearly better in patients who have not received lorlatinib.
- Limitations: Single-arm trial; no comparison group; no advantage in progression-free survival or survival has been shown. In patients who had received lorlatinib, median progression-free survival was 4.6 months.
- Side effects and Türkiye: The most important side effect is a rise in liver enzymes (grade 3 or higher in one in five patients); regular blood tests are essential. As of November 2026, neladalkib is not licensed in Türkiye.
Why does this matter?
ALK-positive lung cancer accounts for about 3-5% of NSCLC cases; it is mostly seen in younger people who have never smoked or have smoked little (lung cancer guide, facts about lung cancer). These patients can live for years with a good quality of life on ALK inhibitors. For example, 60% of patients treated with first-line lorlatinib are still living without disease progression after five years.
However, resistance develops over time in most patients. The most common cause of resistance after alectinib is a mutation called G1202R; after lorlatinib, "compound mutations", in which more than one mutation combines in the same gene, often appear (how do cancer cells develop resistance?). At this point the options narrow, and treatment usually moves to chemotherapy. Neladalkib was designed precisely to target these resistance mutations and to penetrate the brain well. One of the topics I discuss most often with my ALK-positive patients in my clinic is the question "what happens when the drug stops working?"; this approval adds a new answer to that question.
- Yes: This is neladalkib's first FDA approval.
- No: It is not the first drug approved for previously treated ALK-positive NSCLC. Lorlatinib was approved in 2018 in a similar patient group, after alectinib or after crizotinib and another ALK inhibitor.
- Unknown: The company's statements that it is "designed to avoid TRK receptors" and is "active against G1202R and compound mutations" describe design features; no comparative trial has shown that these features are clinically a first or superior.
What is neladalkib?
Neladalkib (Nelkarmi) is a new-generation oral ALK inhibitor used in ALK-positive lung cancer. It is designed to target G1202R and compound mutations, which cause resistance to earlier ALK drugs, to penetrate the brain well and to avoid TRK receptors. It is taken by mouth at 150 mg once daily.
ALK inhibitors have developed in generations. Each new generation was designed to overcome the resistance mutations that arose against the previous one and to be more effective in brain metastases. Lorlatinib is a strong drug in this respect; however, in some patients it can cause central nervous system side effects such as weight gain, high cholesterol, and mood and cognitive changes. The developers of neladalkib, believing that some of these side effects might be linked to the blocking of receptors called TRK, designed the drug so that it does not affect these receptors (brigatinib).
Figure 1 · Generations of ALK inhibitors
Resistance mutations and new drugs
What does accelerated approval mean?
In serious diseases and where treatment options are limited, the FDA can grant accelerated approval based on a measure that is reasonably likely to predict clinical benefit (for example, the tumour response rate). For this approval to become permanent, the drug's real clinical benefit, such as delaying disease progression or prolonging survival, must be shown in confirmatory trials; if it is not, the approval can be withdrawn (an example of accelerated approval). The FDA had also granted neladalkib priority review, breakthrough therapy and orphan drug designations.
The ALKOVE-1 trial: how was it done?
ALKOVE-1 is an international, single-arm, open-label phase 1/2 trial in ALK-positive solid tumours. The FDA approval is based on two cohorts of the trial made up of previously treated patients with lung cancer: 67 patients who, in the advanced setting, had received only alectinib as their single ALK inhibitor, and 155 patients who had received at least two ALK inhibitors plus platinum-based chemotherapy. The primary endpoints were objective response rate and duration of response, with tumours assessed by an independent, blinded central committee (what is a clinical trial?).
The trial has no comparison group. It is therefore not possible to know from these data how much neladalkib affects disease progression or survival compared with another treatment. The randomised phase 3 ALKAZAR trial, comparing neladalkib with alectinib in the first line, is ongoing.
Figure 2 · Design of the ALKOVE-1 trial
Phase 1/2, single-arm, open-label
Results: who responds, and how much?
According to FDA data, tumours shrank markedly in 49% (95% CI 37-62%) of the 67 patients who had received only alectinib. Among responders, the response lasted at least 6 months in 76% and at least 12 months in 52%. In the 155 patients who had received at least two ALK inhibitors and chemotherapy, the response rate was 32% (95% CI 24-40%); among responders, the response lasted at least 6 months in 69% and at least 12 months in 51%. In other words, responses are seen less often in more heavily pretreated patients, but in half of those who do respond, the response lasts more than a year.
In patients with measurable brain metastases, the intracranial response rate was 55% after alectinib (11 of 20 patients; in 25%, the brain lesions disappeared completely) and 26% after more than one ALK inhibitor (14 of 53 patients). These data are important because brain metastases are one of the most significant problems in ALK-positive disease (local treatments for brain metastases).
ALKOVE-1: who responds, and how much?
Objective response rate, %; independent central assessment. No control group; dark bars show the intracranial response.
The first two rows are the cohorts on which the FDA approval was based. The lorlatinib and G1202R subgroups come from the broader 253-patient analysis (November 2025). The brain rows show the intracranial response rate in patients with measurable brain metastases. Median progression-free survival was 14.5 months in lorlatinib-naive patients and 4.6 months in lorlatinib-exposed patients.
Lorlatinib-naive or lorlatinib-exposed?
The broader 253-patient analysis presented in November 2025 shows that the most important distinction when reading the results is lorlatinib. In 63 patients who had not received lorlatinib, the response rate was 46% and median progression-free survival was 14.5 months; in 190 patients who had received lorlatinib, the response rate was 26% and median progression-free survival was 4.6 months. In patients who responded after lorlatinib, the median duration of response was 17.6 months; in other words, although responses are seen less often, they can last a long time when they do occur. In 47 patients with the G1202R mutation, the most common cause of resistance after alectinib, the response rate was 68%. Early data in 44 patients who had not yet received an ALK inhibitor reported a response rate of 86%; this group is not covered by the approval.
Indirect comparison with lorlatinib
Today, lorlatinib is the most commonly used option after alectinib. In the phase 2 trial of lorlatinib, the response rate was 42.9% after one second-generation ALK inhibitor and 38.7% after two or more ALK inhibitors. At first glance the figures look similar; however, there is an important difference: most patients in neladalkib's second cohort had previously received lorlatinib, whereas the patients in the lorlatinib trial, naturally, had not. The two figures therefore do not reflect the same stage of treatment. There is no trial comparing the two drugs directly (reading research results correctly).
Indirect comparison: with lorlatinib
Objective response rate, %; neladalkib (coloured) and lorlatinib phase 2 (grey).
Most patients in the neladalkib ≥2-inhibitor cohort had previously received lorlatinib, whereas the patients in the lorlatinib trial had not received lorlatinib. The two figures therefore do not reflect the same stage of the same disease. Comparisons across different studies are indirect; patient populations, prior treatments and follow-up times differ.
Side effects: the liver needs close monitoring
The most common and most important side effect of neladalkib is a rise in liver enzymes (ALT, AST). In 656 patients treated at the recommended dose, raised ALT was seen in 47% (grade 3 or higher in 20%) and raised AST in 44% (grade 3 or higher in 16%). These rises mostly caused no symptoms and resolved with a treatment interruption or dose reduction (liver enzymes). Other common side effects were constipation, taste disturbance, musculoskeletal pain, peripheral neuropathy (numbness in the hands and feet), oedema and fatigue. The dose was reduced in 17% of patients, and the drug was stopped because of side effects in 5%; the most common reason was liver toxicity.
Side effects: the liver stands out
656 patients treated at the recommended dose; proportion of patients, %.
Liver enzyme rises were mostly symptom-free and resolved with a treatment interruption or dose reduction. The FDA label carries warnings for liver and kidney toxicity, ocular side effects, raised muscle enzyme (CPK) and risk in pregnancy. Median treatment duration was 6 months.
- Liver: Liver tests should be monitored at frequent intervals during the first months of treatment. Enhanced liver monitoring has also been added to the ALKAZAR trial protocol.
- Kidney and muscle enzyme: The FDA label carries warnings for renal toxicity and raised muscle enzyme (CPK); muscle pain or weakness should be reported.
- Eyes: There is a warning for ocular side effects such as visual disturbance; any new visual complaint requires an eye examination.
- Pregnancy: It can harm the baby during pregnancy; effective contraception is required.
- Difference from lorlatinib: High cholesterol, weight gain, and mood or cognitive changes, which are common with lorlatinib, were not reported among neladalkib's prominent side effects. However, there is no direct safety comparison between the two drugs.
The current treatment sequence in ALK-positive lung cancer
In the first line, alectinib, brigatinib, lorlatinib or ensartinib is used; the drug with the strongest long-term follow-up data is lorlatinib. In patients who can have surgery, post-operative alectinib is also an option (treatment before and after surgery in ALK-positive lung cancer). When the disease progresses, the cause of resistance should, where possible, be investigated with a re-biopsy or blood test: is there a new mutation in the ALK gene, has an escape route outside ALK opened up, or has the tumour transformed into small cell lung cancer? The answer changes the treatment. I also explained similar reasoning in targeted therapy in my articles on EGFR, the EGFR 2026 update, KRAS G12C and HER2-mutant lung cancer.
| Situation | FDA-approved options | Note |
|---|---|---|
| First line | Alectinib, brigatinib, lorlatinib, ensartinib (crizotinib now rarely) | With lorlatinib, 60% of patients progression-free at 5 years |
| After alectinib | Lorlatinib; neladalkib (November 2026, accelerated) | Response rate 49% for neladalkib; no direct comparison |
| After ≥2 ALK inhibitors and platinum-based chemotherapy | Neladalkib (November 2026, accelerated) | Response rate 32%; median PFS 4.6 months after lorlatinib |
| After targeted therapy | Platinum-based chemotherapy (± bevacizumab or immunotherapy in selected patients) | Immunotherapy has limited effect in ALK-positive disease |
| Limited progression | Radiotherapy or surgery to the progressing site while continuing the drug | Especially for brain metastases |
Figure 3 · Treatment sequence in ALK-positive lung cancer
Where does neladalkib fit?
When the disease progresses at a limited number of sites, giving stereotactic radiotherapy to these sites without stopping the drug is an approach I use often (stereotactic radiotherapy and targeted drugs). I summarised recent advances in targeted therapies for lung cancer in my articles on the 2025 FDA approvals and the WCLC 2026 summary.
The situation in Türkiye
As of November 2026, neladalkib is not licensed in Türkiye. Following the FDA approval, it can only be brought in with named-patient import authorisation from the Turkish Medicines and Medical Devices Agency (TİTCK); in this case, SGK reimbursement should not be expected, and the cost may be very high (unlicensed imported medicines, oncology drug prices). Lorlatinib, the most important option after alectinib, is licensed in Türkiye and, under the conditions set out in the SUT, is also reimbursed for progression after a prior ALK inhibitor (SGK reimbursement rules). For this reason, in Türkiye lorlatinib will for now remain the first choice after alectinib for most patients; neladalkib will come into consideration mainly for patients whose disease progresses after lorlatinib and who cannot take part in a suitable clinical trial.
Questions you can ask your doctor
- My disease has progressed; can a re-biopsy or blood test be done to find out the cause of resistance?
- Do I have G1202R or a compound ALK mutation; would this change the choice of drug?
- Is lorlatinib, neladalkib or a clinical trial more suitable for me?
- If I take neladalkib, how often will my liver tests be checked?
- This drug is not licensed in Türkiye; how do the import process and its cost work?
- "Since the FDA approved it, it has been proven to prolong survival." No. This is an accelerated approval based on the response rate; there are no survival data.
- "Neladalkib is better than lorlatinib." This cannot be said. The two drugs have not been compared directly; in patients who have received lorlatinib, the effect of neladalkib is more limited.
- "A single-arm trial is unreliable." Single-arm trials provide valuable information for targeted therapies; however, they are limited in showing the size of the effect and its impact on survival. That is why the approval is provisional.
- "Targeted drugs have no side effects." Wrong. With neladalkib, a rise in liver enzymes is common and can be severe in one in five patients.
- "When the drug stops working, there are no options left." In ALK-positive disease there are several targeted drugs that can be used in sequence after resistance, as well as chemotherapy, local treatments and clinical trials.
Frequently Asked Questions
- What is neladalkib?
- Neladalkib (Nelkarmi) is a new-generation oral ALK inhibitor used in ALK-positive lung cancer. It is designed to target mutations that cause resistance to earlier ALK drugs and to penetrate the brain well. The FDA granted it accelerated approval on 17 November 2026.
- Who does the FDA approval of neladalkib cover?
- It covers adults with unresectable locally advanced or metastatic ALK-positive NSCLC who, in the advanced setting, have previously received either only alectinib or at least two ALK inhibitors plus platinum-based chemotherapy.
- How effective is neladalkib?
- In the ALKOVE-1 trial, the response rate was 49% after alectinib and 32% after more than one ALK inhibitor and chemotherapy. In about half of responders, the response lasted longer than 12 months. Because the trial is single-arm, its effect on survival is unknown.
- Is neladalkib available in Türkiye?
- As of November 2026, neladalkib is not licensed in Türkiye. It can be obtained through named-patient import, but SGK reimbursement should not be expected. Lorlatinib, which is used after alectinib, is licensed and reimbursed in Türkiye.
Glossary
- ALK-positive
- A change in which the ALK gene fuses with another gene, so that it stays permanently active and drives tumour growth.
- ALK inhibitor
- A targeted drug that stops tumour growth by blocking the ALK protein.
- NSCLC
- Non-small cell lung cancer; about 85% of lung cancers.
- G1202R
- A common mutation in the ALK gene that causes resistance, particularly to second-generation drugs.
- Compound mutation
- The presence of more than one mutation together in the same gene; it usually appears after lorlatinib.
- TRK
- A family of receptors with important roles in the nervous system; blocking them has been linked to certain neurological side effects.
- Accelerated approval
- A provisional FDA approval based on a measure that predicts clinical benefit, requiring a confirmatory trial.
- Objective response rate
- The proportion of patients whose tumour shrinks markedly or disappears.
- Single-arm trial
- A trial in which all patients receive the same treatment and there is no comparison group.
- ALT / AST
- Enzymes found in liver cells; raised levels in the blood can indicate liver damage.
DROZDOGAN Academy Commentary
Neladalkib looks like a well-designed and effective drug for the post-resistance phase of ALK-positive lung cancer. However, the approval rests on response rates from a single-arm trial; its true place will be determined by randomised trials.
⚡ Why it matters
Until now there was no effective targeted therapy for patients whose disease progressed after lorlatinib, and chemotherapy was the main option. In this group, neladalkib can provide durable responses, albeit in a limited share of patients; it also shows activity in patients with the G1202R mutation and with brain metastases.
✅ Strengths
Independent central assessment; a large, heavily pretreated patient group; responses lasting more than a year in half of responders; activity in the brain; a low rate of stopping because of side effects (5%); some lorlatinib-specific side effects not prominent.
⚠️ Limitations
No control group; no comparison of progression-free survival or survival; limited activity after lorlatinib (response 26%, median progression-free survival 4.6 months); liver toxicity is common and requires close monitoring; no direct comparison with lorlatinib.
🩺 In practice
In my patients whose disease progresses after alectinib, lorlatinib remains my first choice because it is licensed and reimbursed in Türkiye. On progression after lorlatinib, I consider neladalkib, especially in patients in good general condition in whom a re-biopsy has shown an ALK mutation. If I start treatment, I monitor liver tests at frequent intervals during the first months. If a suitable clinical trial is available, I always recommend this to my patients as well.
❓ Open questions
Will neladalkib outperform alectinib in the first line in the ALKAZAR trial? In the first line, which is the better start: lorlatinib or neladalkib? Which mutation profile after lorlatinib predicts response to neladalkib? How does liver toxicity evolve with long-term use?
Bottom line: Neladalkib is a valuable new option for patients with resistant ALK-positive lung cancer. Its activity is more pronounced after alectinib and more limited after lorlatinib. Whether the accelerated approval becomes permanent, and the drug's place in the treatment sequence, will be clarified by randomised trials.
- This article was prepared in November 2026.
- Response rates, durations of response and intracranial response rates for the approval cohorts are based on the FDA announcement and the company statement. The lorlatinib subgroups, the G1202R data, the early first-line data and the safety rates are taken from the broader 253-patient and 656-patient analyses presented in November 2025; these analyses are not identical to the approval cohorts.
- At the time of writing, I could not verify a full peer-reviewed publication of ALKOVE-1. The comparison with lorlatinib is indirect and reflects different patient groups.
- Please check licensing and reimbursement information for Türkiye against current TİTCK and SGK sources.
- The diagrams are simplified. The Academy commentary is my own. This article is not medical advice; make your treatment decisions together with your doctor.
References
- U.S. FDA. FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer (17 November 2026). fda.gov
- GSK. Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer (17 November 2026). gsk.com
- Targeted Oncology. FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC (November 2026). targetedonc.com
- OncLive. Neladalkib Proves Effective in TKI-Pretreated Advanced ALK+ NSCLC: ALKOVE-1 pivotal topline data (17 November 2025). onclive.com
- ALKOVE-1, NCT05384626; ALKAZAR, NCT06765109. clinicaltrials.gov
- Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 2021. doi
- Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol 2024. doi
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566. doi
Was this article helpful?
Your feedback helps us improve our content.




